Clinical Trial

Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells

Study acronym: RT-CAR
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to demonstrate that it is possible to report in real time (less than 3 weeks) to the hematologist the results of the molecular minimal residual disease (MRD) based on blood circulating tumor DNA (ctDNA) assessment taken approximately 7 days after the reinjection of the CAR-T cells, in order to be able to anticipate a possible progression of the disease and to be able to propose salvage or earlier adjuvant therapy to improve patient prognosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-12-22.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-12-29
Trial Details
NCT Number NCT05675982
Lead Sponsor Centre Henri Becquerel
Conditions Diffuse Large B Cell Lymphoma
Enrollment 40 participants
Start Date 2023-01-13
Primary Completion 2025-09-08 (estimated)
Study Completion 2026-09-08 (estimated)
Updated on ClinicalTrials.gov 2026-01-02